Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.

Yang E, Gardner MR, Zhou AS, Farzan M, Arvin AM, Oliver SL.

PLoS One. 2018 Oct 25;13(10):e0206365. doi: 10.1371/journal.pone.0206365. eCollection 2018.

2.

Distinctive Roles for Type I and Type II Interferons and Interferon Regulatory Factors in the Host Cell Defense against Varicella-Zoster Virus.

Sen N, Sung P, Panda A, Arvin AM.

J Virol. 2018 Oct 12;92(21). pii: e01151-18. doi: 10.1128/JVI.01151-18. Print 2018 Nov 1.

3.

Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells.

Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, Vasquez J, Spitzer MH, Lazarus NH, Jones JJ, Ochsenbauer C, McCune JM, Butcher EC, Arvin AM, Sen N, Greene WC, Roan NR.

Cell Rep. 2017 Jul 25;20(4):984-998. doi: 10.1016/j.celrep.2017.06.087.

4.

Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.

Oliver SL, Yang E, Arvin AM.

Curr Clin Microbiol Rep. 2016 Dec;3(4):204-215. doi: 10.1007/s40588-016-0044-4. Epub 2016 Sep 9.

5.

The Glycoprotein B Cytoplasmic Domain Lysine Cluster Is Critical for Varicella-Zoster Virus Cell-Cell Fusion Regulation and Infection.

Yang E, Arvin AM, Oliver SL.

J Virol. 2016 Dec 16;91(1). pii: e01707-16. doi: 10.1128/JVI.01707-16. Print 2017 Jan 1.

6.

Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.

Oliver SL, Yang E, Arvin AM.

J Virol. 2016 Dec 16;91(1). pii: e01613-16. doi: 10.1128/JVI.01613-16. Print 2017 Jan 1.

7.

Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.

Yang E, Arvin AM, Oliver SL.

J Virol. 2016 Jul 27;90(16):7567-78. doi: 10.1128/JVI.00792-16. Print 2016 Aug 15.

8.

Mutational analysis of varicella-zoster virus (VZV) immediate early protein (IE62) subdomains and their importance in viral replication.

Khalil MI, Che X, Sung P, Sommer MH, Hay J, Arvin AM.

Virology. 2016 May;492:82-91. doi: 10.1016/j.virol.2016.02.012. Epub 2016 Feb 23.

9.

Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.

Chen SF, Holmes TH, Slifer T, Ramachandran V, Mackey S, Hebson C, Arvin AM, Lewis DB, Dekker CL.

J Pediatric Infect Dis Soc. 2016 Mar;5(1):14-20. doi: 10.1093/jpids/piu089. Epub 2014 Sep 11.

10.

Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.

Sen N, Arvin AM.

J Virol. 2016 Jan 20;90(7):3284-7. doi: 10.1128/JVI.03375-14. Review.

11.

Single cell mass cytometry reveals remodeling of human T cell phenotypes by varicella zoster virus.

Sen N, Mukherjee G, Arvin AM.

Methods. 2015 Nov 15;90:85-94. doi: 10.1016/j.ymeth.2015.07.008. Epub 2015 Jul 23. Review.

12.

A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL.

Xing Y, Oliver SL, Nguyen T, Ciferri C, Nandi A, Hickman J, Giovani C, Yang E, Palladino G, Grose C, Uematsu Y, Lilja AE, Arvin AM, Carfí A.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6056-61. doi: 10.1073/pnas.1501176112. Epub 2015 Apr 27.

13.

Varicella-zoster virus (VZV) origin of DNA replication oriS influences origin-dependent DNA replication and flanking gene transcription.

Khalil MI, Sommer MH, Hay J, Ruyechan WT, Arvin AM.

Virology. 2015 Jul;481:179-86. doi: 10.1016/j.virol.2015.02.049. Epub 2015 Mar 17.

14.

Autophagic flux without a block differentiates varicella-zoster virus infection from herpes simplex virus infection.

Buckingham EM, Carpenter JE, Jackson W, Zerboni L, Arvin AM, Grose C.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):256-61. doi: 10.1073/pnas.1417878112. Epub 2014 Dec 22.

15.

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N.

JAMA Neurol. 2015 Jan;72(1):31-9. doi: 10.1001/jamaneurol.2014.3065.

16.

Single-cell mass cytometry analysis of human tonsil T cell remodeling by varicella zoster virus.

Sen N, Mukherjee G, Sen A, Bendall SC, Sung P, Nolan GP, Arvin AM.

Cell Rep. 2014 Jul 24;8(2):633-45. doi: 10.1016/j.celrep.2014.06.024. Epub 2014 Jul 17.

17.

The cytoplasmic domain of varicella-zoster virus glycoprotein H regulates syncytia formation and skin pathogenesis.

Yang E, Arvin AM, Oliver SL.

PLoS Pathog. 2014 May 29;10(5):e1004173. doi: 10.1371/journal.ppat.1004173. eCollection 2014 May.

18.

Molecular mechanisms of varicella zoster virus pathogenesis.

Zerboni L, Sen N, Oliver SL, Arvin AM.

Nat Rev Microbiol. 2014 Mar;12(3):197-210. doi: 10.1038/nrmicro3215. Epub 2014 Feb 10. Review.

19.

ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection.

Che X, Oliver SL, Reichelt M, Sommer MH, Haas J, Roviš TL, Arvin AM.

J Virol. 2013 May;87(9):5106-17. doi: 10.1128/JVI.00102-13. Epub 2013 Feb 20.

20.

Identification of a hydrophobic domain in varicella-zoster virus ORF61 necessary for ORF61 self-interaction, viral replication, and skin pathogenesis.

Wang L, Rajamani J, Sommer M, Zerboni L, Arvin AM.

J Virol. 2013 Apr;87(7):4075-9. doi: 10.1128/JVI.02963-12. Epub 2013 Jan 23.

21.

An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis.

Oliver SL, Brady JJ, Sommer MH, Reichelt M, Sung P, Blau HM, Arvin AM.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1911-6. doi: 10.1073/pnas.1216985110. Epub 2013 Jan 15.

22.

Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, Beeler J, Arvin AM.

J Infect Dis. 2013 Feb 15;207(4):574-82. doi: 10.1093/infdis/jis719. Epub 2013 Jan 8.

23.

The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.

Peters GA, Tyler SD, Carpenter JE, Jackson W, Mori Y, Arvin AM, Grose C.

J Virol. 2012 Oct;86(19):10695-703. doi: 10.1128/JVI.01067-12. Epub 2012 Jul 25.

24.

3D reconstruction of VZV infected cell nuclei and PML nuclear cages by serial section array scanning electron microscopy and electron tomography.

Reichelt M, Joubert L, Perrino J, Koh AL, Phanwar I, Arvin AM.

PLoS Pathog. 2012;8(6):e1002740. doi: 10.1371/journal.ppat.1002740. Epub 2012 Jun 7.

25.

Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis.

Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J, Arvin AM.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5. doi: 10.1073/pnas.1114232109. Epub 2011 Dec 21.

26.

Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism.

Vleck SE, Oliver SL, Brady JJ, Blau HM, Rajamani J, Sommer MH, Arvin AM.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18412-7. doi: 10.1073/pnas.1111333108. Epub 2011 Oct 24.

27.

Varicella zoster virus ORF25 gene product: an essential hub protein linking encapsidation proteins and the nuclear egress complex.

Vizoso Pinto MG, Pothineni VR, Haase R, Woidy M, Lotz-Havla AS, Gersting SW, Muntau AC, Haas J, Sommer M, Arvin AM, Baiker A.

J Proteome Res. 2011 Dec 2;10(12):5374-82. doi: 10.1021/pr200628s. Epub 2011 Oct 26.

28.

Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin.

Wang L, Oliver SL, Sommer M, Rajamani J, Reichelt M, Arvin AM.

PLoS Pathog. 2011 Aug;7(8):e1002157. doi: 10.1371/journal.ppat.1002157. Epub 2011 Aug 25.

29.

Varicella-zoster virus infection triggers formation of an interleukin-1β (IL-1β)-processing inflammasome complex.

Nour AM, Reichelt M, Ku CC, Ho MY, Heineman TC, Arvin AM.

J Biol Chem. 2011 May 20;286(20):17921-33. doi: 10.1074/jbc.M110.210575. Epub 2011 Mar 8.

30.

Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells.

Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM.

J Virol. 2011 May;85(9):4095-110. doi: 10.1128/JVI.02596-10. Epub 2011 Feb 23.

31.

Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus.

Reichelt M, Wang L, Sommer M, Perrino J, Nour AM, Sen N, Baiker A, Zerboni L, Arvin AM.

PLoS Pathog. 2011 Feb 3;7(2):e1001266. doi: 10.1371/journal.ppat.1001266.

32.

Identification and functional characterization of the Varicella zoster virus ORF11 gene product.

Che X, Oliver SL, Sommer MH, Rajamani J, Reichelt M, Arvin AM.

Virology. 2011 Mar 30;412(1):156-66. doi: 10.1016/j.virol.2010.12.055. Epub 2011 Jan 26.

33.

Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine.

Pahud BA, Glaser CA, Dekker CL, Arvin AM, Schmid DS.

J Infect Dis. 2011 Feb 1;203(3):316-23. doi: 10.1093/infdis/jiq066. Epub 2010 Dec 21.

34.

Varicella-zoster virus. Preface.

Abendroth A, Arvin AM, Moffat JF.

Curr Top Microbiol Immunol. 2010;342:v-vi. No abstract available.

PMID:
20973159
35.
36.

Herpes simplex virus-1 induces expression of a novel MxA isoform that enhances viral replication.

Ku CC, Che XB, Reichelt M, Rajamani J, Schaap-Nutt A, Huang KJ, Sommer MH, Chen YS, Chen YY, Arvin AM.

Immunol Cell Biol. 2011 Feb;89(2):173-82. doi: 10.1038/icb.2010.83. Epub 2010 Jul 6.

37.

Varicella-zoster virus T cell tropism and the pathogenesis of skin infection.

Arvin AM, Moffat JF, Sommer M, Oliver S, Che X, Vleck S, Zerboni L, Ku CC.

Curr Top Microbiol Immunol. 2010;342:189-209. doi: 10.1007/82_2010_29. Review.

38.

Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis.

Arvin AM, Oliver S, Reichelt M, Moffat JF, Sommer M, Zerboni L, Berarducci B.

Curr Top Microbiol Immunol. 2010;342:129-46. doi: 10.1007/82_2009_1. Review.

PMID:
20186616
39.

Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection.

Huch JH, Cunningham AL, Arvin AM, Nasr N, Santegoets SJ, Slobedman E, Slobedman B, Abendroth A.

J Virol. 2010 Apr;84(8):4060-72. doi: 10.1128/JVI.01450-09. Epub 2010 Feb 3.

40.

Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.

Berarducci B, Rajamani J, Zerboni L, Che X, Sommer M, Arvin AM.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):282-7. doi: 10.1073/pnas.0912373107. Epub 2009 Dec 4.

41.

Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood.

Hanna-Wakim R, Yasukawa LL, Sung P, Fang M, Sullivan B, Rinki M, DeHovitz R, Arvin AM, Gans HA.

J Infect Dis. 2009 Dec 15;200(12):1921-7. doi: 10.1086/648375.

PMID:
19909079
42.

Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model.

Vleck SE, Oliver SL, Reichelt M, Rajamani J, Zerboni L, Jones C, Zehnder J, Grose C, Arvin AM.

J Virol. 2010 Jan;84(1):141-52. doi: 10.1128/JVI.01338-09.

43.

Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo.

Oliver SL, Sommer M, Zerboni L, Rajamani J, Grose C, Arvin AM.

J Virol. 2009 Aug;83(15):7495-506. doi: 10.1128/JVI.00400-09. Epub 2009 May 27.

44.

Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis.

Wang L, Sommer M, Rajamani J, Arvin AM.

J Virol. 2009 Aug;83(15):7560-72. doi: 10.1128/JVI.00118-09. Epub 2009 May 20.

45.

One step closer to a CMV vaccine.

Dekker CL, Arvin AM.

N Engl J Med. 2009 Mar 19;360(12):1250-2. doi: 10.1056/NEJMe0900230. No abstract available.

PMID:
19297578
46.
47.

Varicella in the fetus and newborn.

Smith CK, Arvin AM.

Semin Fetal Neonatal Med. 2009 Aug;14(4):209-17. doi: 10.1016/j.siny.2008.11.008. Epub 2008 Dec 19. Review.

PMID:
19097954
48.

Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry.

Berarducci B, Rajamani J, Reichelt M, Sommer M, Zerboni L, Arvin AM.

J Virol. 2009 Jan;83(1):228-40. doi: 10.1128/JVI.00913-08. Epub 2008 Oct 22.

49.

Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.

Oliver SL, Zerboni L, Sommer M, Rajamani J, Arvin AM.

J Virol Methods. 2008 Dec;154(1-2):182-93. doi: 10.1016/j.jviromet.2008.07.033. Epub 2008 Sep 24.

50.

Influence of prior influenza vaccination on antibody and B-cell responses.

Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB.

PLoS One. 2008 Aug 20;3(8):e2975. doi: 10.1371/journal.pone.0002975.

Supplemental Content

Loading ...
Support Center